Join our daily newsletter At The Bell to receive exclusive market insights
- Anteris Technologies (AVR) successfully treats eight more patients as part of its ongoing first-in-human DurAVR Transcatheter Heart Valve (THV) study in Tbilisi, Georgia
- Data from the latest cohort will be reviewed at the 30-day follow-up which is the key inflexion point for indicating ongoing valve performance
- CEO Wayne Paterson says Anteris is “thrilled” with the ongoing progress and the veracity of the results so far
- As part of the trial, physician Dr Karl Poon became the first Australian doctor to implant a patient with the DurAVR THV
- AVR shares are down 4 per cent and trading at $21.12 at midday AEST.
Anteris Technologies (AVR) has successfully treated eight more patients as part of its ongoing first-in-human DurAVR Transcatheter Heart Valve (THV) study in Tbilisi, Georgia.
The company said all patients enrolled in the study had done “exceptionally well”, and data from the latest cohort would be reviewed at the 30-day follow-up which was the key inflexion point for indicating ongoing valve performance.
Anteris Chief Medical Officer Chris Meduri is overseeing the study, including the initial five aortic stenosis patients implanted with the DurAVR THV last November at the Tbilisi Heart and Vascular Clinic.
CEO Wayne Paterson said Anteris was thrilled with the ongoing progress and the veracity of the results so far.
“The company continues to progress its clinical program, and I look forward to updating the market in the near future,” Mr Paterson said.
Anteris said as part of the trial, physician Dr Karl Poon became the first Australian doctor to implant a patient with the DurAVR THV.
The product is designed to be a functional cure for severe aortic stenosis — a condition where the heart’s aortic valve narrows, reducing blood flow to the body and forcing the heart to work harder.
Anteris’ DurAVR 3D single-piece aortic heart valve replacement is made to address the needs of younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient’s lifetime.
AVR shares were down 4 per cent and trading at $21.12 at midday AEST.
